Vitamin D levels in adult patients with hemophilia

Hemophilia A and B are hereditary diseases due to X-related recessive recurrence seen in male children of female carriers. The coagulation FVIII and FIX deficiency result in a clinic with hemarthrosis and hematoma bleeds, especially in the joints. In this study, we aimed to measure Vitamin D levels which are thought to be important in bone development and destruction in hemophilia patients and to measure some important parameters in bone metabolism and to show the relation with hemophilia. For this study, 40 male hemophiliacs (32 hemophilia A and 8 haemophilia B) and 40 healthy adults were included in the study between the ages of 18-65. We measured Vitamin D (21,86 ± 8,03 ng/mL for hemophilia, 25,46 ± 6,09 ng/mL for control, Ca, P, PTH and ALP levels in the studied subjects. The age of the cases (33,40 ± 11,44 years for hemophilia, 33,92 ± 10,00 years for control, p> 0,05) and BMI (25,81 ± 5,33 kg/m2 for hemophilia, 43 ± 3.97 kg/m2 for control, p> 0.05) were determined. Vitamin D (21,74 ± 5,71 ng/mL for hemophilia A, 25,46 ± 6,09 ng/mL for control, p <0,05) was different between hemophilia A and control groups. There was no significant difference between hemophilia B and Hemophilia A and control in terms of Vitamin D (p> 0.05). In our study Vitamin D values were lower in cases with hemophilia A. In these cases, especially because knee joint bleeds are frequent, these cases act less than normal people. Therefore, Vitamin D levels in these cases should be followed up frequently and should be treated in the absence.